Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/68031
Title: Cardiovascular disease incidence projections in the TREAT Asia HIV Observational Database (TAHOD)
Authors: Rimke Bijker
Nagalingeswaran Kumarasamy
Sasisopin Kiertiburanakul
Sanjay Pujari
Wilson Lam
Romanee Chaiwarith
Wing W. Wong
Adeeba Kamarulzaman
Pacharee Kantipong
Anchalee Avihingsanon
Kinh V. Nguyen
Junko Tanuma
Oon Tek Ng
Benedict L.H. Sim
Tuti P. Merati
Jun Y. Choi
Rossana Ditangco
Evy Yunihastuti
Ly P. Sun
Cuong D. Do
Jeremy Ross
Matthew Law
Authors: Rimke Bijker
Nagalingeswaran Kumarasamy
Sasisopin Kiertiburanakul
Sanjay Pujari
Wilson Lam
Romanee Chaiwarith
Wing W. Wong
Adeeba Kamarulzaman
Pacharee Kantipong
Anchalee Avihingsanon
Kinh V. Nguyen
Junko Tanuma
Oon Tek Ng
Benedict L.H. Sim
Tuti P. Merati
Jun Y. Choi
Rossana Ditangco
Evy Yunihastuti
Ly P. Sun
Cuong D. Do
Jeremy Ross
Matthew Law
Keywords: Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Jan-2019
Abstract: ©2019 International Medical Press Background: We aimed to project the 10-year future incidence of cardiovascular disease (CVD) and model several intervention scenarios based on a multi-site Asian HIV-positive cohort. Methods: Analyses were based on patients recruited to the TREAT Asia HIV Observational Database (TAHOD), consisting of 21 sites in 12 countries. Patients on triple antiretroviral therapy (ART) were included if they were alive, without previous CVD, and had data on CVD risk factors. Annual new CVD events for 2019–2028 were estimated with the D:A:D equation, accounting for age- and sex-adjusted mortality. Modelled intervention scenarios were treatment of high total cholesterol, low high-density lipoprotein cholesterol (HDL) or high blood pressure, abacavir or lopinavir substitution, and smoking cessation. Results: Of 3,703 included patients, 69% were male, median age was 46 (IQR 40–53) years and median time since ART initiation was 9.8 years (IQR 7.5–14.1). Cohort incidence rates of CVD were projected to increase from 730 per 100,000 person-years (pys) in 2019 to 1,432 per 100,000 pys in 2028. In the modelled intervention scenarios, most events can be avoided by smoking cessation, abacavir substitution, lopinavir substitution, decreasing total cholesterol, treating high blood pressure and increasing HDL. Conclusions: Our projections suggest a doubling of CVD incidence rates in Asian HIV-positive adults in our cohort. An increase in CVD can be expected in any ageing population, however, according to our models, this can be close to averted by interventions. Thus, there is an urgent need for risk screening and integration of HIV and CVD programmes to reduce the future CVD burden.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85074380127&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/68031
ISSN: 20402058
13596535
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.